AIM: To investigate the effect of lowering intraocular pressure(IOP)and side effect of travoprost(TA)on phacoemulsification and intraoclular lens(IOL)implantation in primary open-angle glaucoma(POAG).

METHODS: Patients with POAG already received surgery of phacoemulsification and IOL implantation were selected by randomized, single-blind, parallel group trial. TA was applied once a day in 43 patients(43 eyes)of treatment group and brinzolamide was used twice in 43 patients(43 eyes)of control group. All patients were observed for 12wk. IOP, ocular symptom and adverse reaction etc. were observed.

RESULTS: The daily average IOP(mean±standard deviation)in the treatment group decreased from(24.20±3.01)mmHg(1mmHg=0.133kPa)to(16.77±2.89)mmHg and that in the control group was from(23.87±3.47)mmHg to(18.81±3.07)mmHg. IOP pre- and pro-treatment within two groups had significant difference(P<0.01), IOP between the groups at each time point had statistical difference(P<0.05). Conjunetival congestion increased and itching in treatment group was obviously more serious than that in the control group, but the treatment could continue. No other ocular and systemic adverse events related to the drugs were found.

CONCLUSION: It is demonstrated that travoprost is highly effective and safe in reducing IOP in POAG already received surgery of phacoemulsification and IOL implantation.